Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

Takeshi Yoshida(Moffitt Cancer Center), Junji Matsui(Eisai (Japan))
British Journal of Cancer
February 25, 2014
Cited by 355


Related Papers